Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-Current Deferred Tax Liability (2022 - 2024)

Historic Non-Current Deferred Tax Liability for Crinetics Pharmaceuticals (CRNX) over the last 3 years, with Q4 2024 value amounting to $9.8 million.

  • Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability fell 48.98% to $9.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $9.8 million, marking a year-over-year decrease of 48.98%. This contributed to the annual value of $9.8 million for FY2024, which is 48.98% down from last year.
  • According to the latest figures from Q4 2024, Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability is $9.8 million, which was down 48.98% from $9.8 million recorded in Q4 2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability registered a high of $9.8 million during Q4 2023, and its lowest value of $453000.0 during Q4 2022.
  • In the last 3 years, Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability had a median value of $9.8 million in 2024 and averaged $6.7 million.
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability surged by 206313.47% in 2023 and then crashed by 48.98% in 2024.
  • Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability (Quarter) stood at $453000.0 in 2022, then skyrocketed by 2063.13% to $9.8 million in 2023, then fell by 0.49% to $9.8 million in 2024.
  • Its last three reported values are $9.8 million in Q4 2024, $9.8 million for Q4 2023, and $453000.0 during Q4 2022.